Centrum für Hämatologie und Onkologie Bethanien

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article, Erratum Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, et al. Conference contribution Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) Sinn BV, Untch M, Karn T, Van Mackelenbergh M, Huober J, Sychra K, Schmitt WD, et al. Conference contribution Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer. (2022) Aktas B, Fehm TN, Welslau M, Mueller V, Lueftner D, Schuetz F, Fasching P, et al. Journal article, Review article Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. (2022) Thomssen C, Fehm TN, Stickeler E, Fasching P, Janni W, Kolberg-Liedtke C, Kolberg HC, et al. Journal article, Review article Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. (2022) Lueftner D, Schuetz F, Stickeler E, Fasching P, Janni W, Kolberg-Liedtke C, Kolberg HC, et al. Journal article, Review article Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. (2022) Fehm TN, Welslau M, Mueller V, Lueftner D, Schuetz F, Fasching P, Janni W, et al. Journal article, Review article Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices (2022) Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Loewe G, Kiani A Journal article Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) Engler T, Fasching P, Lueftner D, Hartkopf AD, Mueller V, Kolberg HC, Hadji P, et al. Journal article Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2021) Marmé F, Solbach C, Michel L, Schneeweiss A, Blohmer JU, Huober J, Fasching P, et al. Journal article